# US 2003/0225121 A1 · Heterocyclylalkylindole or-azaindole compounds as 5-hydroxytryptamine-6 ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0225121 A1
- Document ID: US20030225121A1
- Status: Published application
- Kind: A1
- Application number: 10/441,850
- Filed: 2003-05-20
- Published: 2003-12-04
- Earliest claimed: 2001-12-20
- Assignees: Wyeth
- Inventors: Ping Zhou; Michael Gerard Kelly; Yanfang Li
- Web page: https://patentgrep.com/patent/US20030225121A1

## CPC

- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/14: containing three or more hetero rings
- C07D 409/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a compound of formula I and the use thereof in the therapeutic treatment of disorders related to or affected by the 5-HT6 receptor. 1

## Claims

### Claim 1

A compound of formula I
26
wherein
Q is SO2, CO, CONR24, CSNR25 or CH2;
W is N or CR2;
X is N or CR9;
Y is NR or CR10R29;
Z is NR21 or CR11R30 with the proviso that when Y is NR then Z must be CR11LR30 and with the further proviso that at least one of Y and Z must be NR or NR21;
n is 0 or an integer of 1 or 2;
R and R21 are each independently H, CNR26NR27R28 or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1, R2 and R9 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR22R23, CNR14NR15R16 SOmR17 NR18R19, OR20 or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
m is 0 or an integer of 1 or 2;
R3 and R4 are each independently H, halogen, C1-C4alkyl or C1-C4haloalkyl or R3 and R4 may be taken together with the atom to which they are attached to form a carbonyl group;
R5 and R6 are each independently H or an optionally substituted C1-C6alkyl group;
R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
R10, R11, R29 and R30 are each independently H or an optionally substituted C1-C6alkyl group;
R12, R13 and R17 are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C1-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4alkyl;
R20, R22 and R23 are each independently H or an optionally substituted C1-C6alkyl group;
R24 and R25 are each independently H or an alkyl, aryl or heteroaryl group each optionally substituted; and
---- represents a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound according to claim 1 wherein n is 1.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein R3 and R4 are H.

### Claim 4 (depends on 1)

The compound according to claim 1 wherein Q is SO2 or CO.

### Claim 5 (depends on 1)

The compound according to claim 1 wherein ---- represents a single bond.

### Claim 6 (depends on 2)

The compound according to claim 2 wherein X is CR9; Y is CR10R29; Z is NR21; R3 and R4 are H; and ---- represents a single bond.

### Claim 7 (depends on 6)

The compound according to claim 6 wherein Q is SO2; R21 is H; R8 is an optionally substituted aryl group; and ---- represents a single bond.

### Claim 8 (depends on 4)

The compound according to claim 4 selected from the group consisting of:
5-fluoro-1-(phenylsulfonyl)-0.3-(piperidin-4-ylmethyl)-1H-indole;
5-fluoro-1-(phenylsulfonyl)-3-(1,2,5,6-tetrahydro-3-pyridinylmethyl)-1H-indole;
4-{[5-fluoro-3-(4-piperidinylmethyl)-1H-indol-1yl]sulfonyl}aniline;
1-[(2,6-dichlorophenyl)sulfonyl]-5-fluoro-3-(4-piperidinylmethyl)-1H-indole;
1-[(3,4-dichloro-2-thienyl)sulfonyl]-5-fluoro-3-(4-piperidinylmethyl)-1H-indole;
5-fluoro-1-(1-naphthylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
1-[(3,4-dimethoxyphenyl)sulfonyl]-5-fluoro-3-(piperidin-4-ylmethyl)-1H-indole;
4-{[5-fluoro-3-(piperidin-4-ylmethyl)-1H-indol-1-yl]sulfonyl}benzonitrile;
8-{[5-fluoro-3-(piperidin-4-ylmethyl)-1H-indol-1-yl]sulfonyl}quinoline;
1-(phenylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-indole;
1-(1-naphthylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-indole;
4-{[3-(piperidin-4-ylmethyl)-1H-indol-1-yl]sulfonyl}phenylamine;
1-[(3,4-dichlorothien-2-yl)sulfonyl]-3-(piperidin-4-ylmethyl)-1H-indole;
1-(phenylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;
1-(1-naphthylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;
4-{[3=-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl]sulfonyl}phenylamine;
1-[(3,4-dichlorothien-2-yl)sulfonyl]-3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;
6-flouro-1-(phenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(1-naphthylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(3,4-dimethoxyphenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(2-chlorophenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(5-chlorothien-2-ylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(2-fluorophenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(3-fluorophenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole; and
a pharmaceutically acceptable salt thereof.

### Claim 9

A method for the treatment of a disorder of the central nervous system related to or affected by the 5-HT6 receptor in a patient in need thereof which comprises providing said patient with a therapeutically effective amount of a compound of formula I
27
wherein
Q is SO2, CO, CONR24, CSNR25 or CH2;
W is N or CR7;
X is N or CR9;
Y is NR or CR10R29;
Z is NR21 or CR11R30 with the proviso that when Y is NR then Z must be CR11R30 and with the further proviso that at least one of Y and Z must be NR or NR21;
n is 0 or an integer of 1 or 2q;
R and R21 are each independently H, CNR26NR27R28, or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1, R2 and R9 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR22R23, CNR14NR15R16, SOmR17, NR18R19OR20, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
m is 0 or an integer of 1 or 2;
R3 and R4 are each independently H, halogen, C1-C4alkyl or C1-C4haloalkyl or R3 and R4 may be taken together with the atom to which they are attached to form a carbonyl group;
R5 and R6 are each independently H or an optionally substituted C1-C6alkyl group;
R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
R10, R11, R29 and R30 are each independently H or an optionally substituted C1-C6alkyl group;
R12, R13 and R17 are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4alkyl;
R20, R22 and R23 are each independently H or an optionally substituted C1-C6alkyl group;
R24 and R25 are each independently H or an alkyl, aryl or heteroaryl group each optionally substituted; and
---- represents a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 9)

The method according to claim 9 wherein said disorder is a mood disorder, a cognitive disorder or a motor disorder.

### Claim 11 (depends on 10)

The method according to claim 10 wherein said disorder is anxiety or depression.

### Claim 12 (depends on 9)

The method according to claim 9 wherein said disorder is schizophrenia.

### Claim 13 (depends on 10)

The method according to claim 10 wherein said disorder is attention deficit disorder or memory loss.

### Claim 14 (depends on 9)

The method according to claim 9 wherein said disorder is caused by alcohol or drug withdrawl.

### Claim 15

A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of formula I
28
wherein
Q is SO2, CO, CONR24, CSNR25 or CH2;
W is N or CR7;
X is N or CR9;
Y is NR or CR10R29;
Z is NR21 or CR11R30 with the proviso that when Y is NR then Z must be CR1LR30 and with the further proviso that at least one of Y and Z must be NR or NR21;
n is 0 or an integer of 1 or 2;
R and R21 are each independently H, CNR26NR27R28, or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted;
R1, R2 and R9 are each independently H, halogen, CN, OCO2R12, CO2R13, CONR22R23, CNR14NR15R16, SOmR17, NR18R19, OR20, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6-cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
m is 0 or an integer of 1 or 2;
R3 and R4 are each independently H, halogen, C1-C4alkyl or C1-C4haloalkyl or R3 and R4 may be taken together with the atom to which they are attached to form a carbonyl group;
R5 and R6 are each independently H or an optionally substituted C1-C6alkyl group;
R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
R10, R11, R29 and R30 are each independently H or an optionally substituted C1-C6alkyl group;
R12, R13 and R1, are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4alkyl;
R20, R22 and R23 are each independently H or an optionally substituted C1-C6alkyl group;
R24 and R25 are each independently H or an alkyl, aryl or heteroaryl group each optionally substituted; and
---- represents a single bond or a double bond; or
a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The composition according to claim 15 having a formula I compound wherein n is 1; and Q is SO2 or CO.

### Claim 17 (depends on 16)

The composition according to claim 16 having a formula I compound wherein R3 and R4 are H; and Q is SO2.

### Claim 18 (depends on 17)

The composition according to claim 17 having a formula I compound wherein X is CR9; Y is CR10R29; Z is NH; R8 is an optionally substituted aryl group; and ---- represents a single bond.

### Claim 19 (depends on 17)

The composition according to claim 17 having a formula I compound selected from the group consisting of:
5-fluoro-1-(phenylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-indole;
5-fluoro-1-(phenylsulfonyl)-3-(1,2,5,6-tetrahydro-3-pyridinylmethyl)-1H-indole;
4-{[5-fluoro-3-(4-piperidinylmethyl)-1H-indol-1yl]sulfonyl}aniline;
1-[(2,6-dichlorophenyl)sulfonyl]-5-fluoro-3-(4-piperidinylmethyl)-1H-indole;
1-[(3,4-dichloro-2-thienyl)sulfonyl]-5-fluoro-3-(4-piperidinylmethyl)-1H-indole;
5-fluoro-1-(1-naphthylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
1-[(3,4-dimethoxyphenyl)sulfonyl]-5-fluoro-3-(piperidin-4-ylmethyl)-1H-indole;
4-{[5-fluoro-3-(piperidin-4-ylmethyl)-1H-indol-1-yl]sulfonyl}benzonitrile;
8-{[5-fluoro-3-(piperidin-4-ylmethyl)-1H-indol-1-yl]sulfonyl}quinoline;
1-(phenylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-indole;
1-(1-naphthylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-indole;
4-{[3-(piperidin-4-ylmethyl)-1H-indol-1-yl]sulfonyl}phenylamine;
1-[(3,4-dichlorothien-2-yl)sulfonyl]-3-(piperidin-4-ylmethyl)-1H-indole;
1-(phenylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;
1-(1-naphthylsulfonyl)-3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;
4-{[3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridin-1-yl]sulfonyl}phenylamine;
1-[(3,4-dichlorothien-2-yl)sulfonyl]-3-(piperidin-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine;
6-flouro-1-(phenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(1-naphthylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(3,4-dimethoxyphenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(2-chlorophenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(5-chlorothien-2-ylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(2-fluorophenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole;
6-flouro-1-(3-fluorophenylsulfonyl)-3-(4-piperidinylmethyl)-1H-indole; and
a pharmaceutically acceptable salt thereof.

### Claim 20

A process for the preparation of a compound of formula Ia′
29
wherein
W is N or CR7;
X is N or CR9;
R1, R2 and R9 are each independently H, halogen, CN, OC2R12, CO2R13, CONR22R23, CNR14NR15R16, SOmR17, NR18R19, OR20, or a C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, C1-C6alkanoyl, aryl or heteroaryl group each optionally substituted;
m is 0 or an integer of 1 or 2;
R7 is H, halogen, or a C1-C6alkyl, C1-C6alkoxy, aryl or heteroaryl group each optionally substituted;
R8 is an optionally substituted C1-C6alkyl, aryl or heteroaryl group;
R12, R13 and R17 are each independently H or an optionally substituted C1-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group;
R14, R15, R16, R18, R19, R26, R27 and R28 are each independently H or C1-C4 alkyl; and
R21 is H, CNR26NR27R28, or a C1-C6alkyl, C3-C6cycloalkyl, cycloheteroalkyl, aryl or heteroaryl group each optionally substituted
which process comprises reacting a compound of formula IVa
30
wherein G represents a protecting group and W, X, R1 and R2 are as defined hereinabove with an arylsulfonyl chloride, R8SO2Cl, wherein R8 is as defined hereinabove in the presence of a base to form the intermediate of formula Va;
31
deprotecting the formula Va compound in the presence of an acid to give the compound of formula Ia′ wherein R2, is H; and optionally reacting said formula Va compound with an alkylating agent, R21-Hal, wherein Hal is Cl, I or Br and R21 is other than H.
